BridgeMD
Prospective, randomized, blinded, comparative study between botulinum toxin and topical capsaicin in the treatment of postmastectomy syndrome. Pilot study
EU CTIS ID: 2024-513609-29-01
What this study is testing
To determine the effectiveness of Botulinum Toxin type A and topical Capsaicin for the treatment of moderate-severe pain in PMS among women who underwent surgery for unilateral breast neoplasia.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women over 18 years of age operated on for unilateral breast neoplasia
- Patients with painful symptoms defining postmastectomy syndrome.
- Patients with moderate-severe pain.
- Signed informed consent form.
You likely can't join if
- Age less than 18 years
- Presence of cognitive-behavioral deficits.
- Patients with bilateral tumor involvement, cases of tumor recurrence, patients referred for non-oncologic breast surgery.
- Non-acceptance to participate in the study.
- Breast tumors in men.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.